IL225018A - Beta tgf barriers for use in reducing myocardial infarction - Google Patents

Beta tgf barriers for use in reducing myocardial infarction

Info

Publication number
IL225018A
IL225018A IL225018A IL22501813A IL225018A IL 225018 A IL225018 A IL 225018A IL 225018 A IL225018 A IL 225018A IL 22501813 A IL22501813 A IL 22501813A IL 225018 A IL225018 A IL 225018A
Authority
IL
Israel
Prior art keywords
reducing
myocardial infarction
tgf beta
adverse consequence
beta antagonists
Prior art date
Application number
IL225018A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL225018A publication Critical patent/IL225018A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
IL225018A 2010-09-01 2013-02-28 Beta tgf barriers for use in reducing myocardial infarction IL225018A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01
PCT/US2011/001536 WO2012030394A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Publications (1)

Publication Number Publication Date
IL225018A true IL225018A (en) 2017-11-30

Family

ID=44654454

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225018A IL225018A (en) 2010-09-01 2013-02-28 Beta tgf barriers for use in reducing myocardial infarction

Country Status (19)

Country Link
US (2) US20130330352A1 (enExample)
EP (1) EP2611831B1 (enExample)
JP (2) JP6377348B2 (enExample)
KR (1) KR101939965B1 (enExample)
CN (1) CN103201292B (enExample)
BR (1) BR112013004850B1 (enExample)
CA (1) CA2809568C (enExample)
CL (1) CL2013000586A1 (enExample)
ES (1) ES2715177T3 (enExample)
IL (1) IL225018A (enExample)
MX (1) MX354535B (enExample)
MY (1) MY165160A (enExample)
NZ (2) NZ608813A (enExample)
PH (1) PH12013500411A1 (enExample)
PL (1) PL2611831T3 (enExample)
RU (1) RU2637088C2 (enExample)
SG (2) SG187953A1 (enExample)
TR (1) TR201903101T4 (enExample)
WO (1) WO2012030394A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010216095B2 (en) * 2009-02-18 2015-10-08 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
TWI664979B (zh) * 2013-03-11 2019-07-11 健臻公司 經生物工程之抗-TGF-β抗體及抗原結合片段
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
EP3368571B1 (en) 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
US9989543B2 (en) 2016-01-11 2018-06-05 Autotelic, Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
JP2019533003A (ja) * 2016-08-11 2019-11-14 プレシセラ,インコーポレイテッド TGF−βアンタゴニストコンジュゲート
EP3628049B1 (en) 2017-05-04 2023-05-10 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
TW202334179A (zh) 2021-09-30 2023-09-01 日商肽夢想股份有限公司 胜肽

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-tgf-베타 항체
US20070014733A1 (en) * 2005-01-31 2007-01-18 O'donnell John P Hydroxylated nebivolol metabolites
MX2007009545A (es) * 2005-02-08 2008-03-11 Genzyme Corp Anticuerpos para tgfbeta.
JP2012515800A (ja) * 2009-01-26 2012-07-12 インターミューン, インコーポレイテッド 急性心筋梗塞および関連障害を処置するための方法
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido

Also Published As

Publication number Publication date
AU2011296574B2 (en) 2015-12-03
PL2611831T3 (pl) 2019-05-31
ES2715177T3 (es) 2019-06-03
EP2611831A1 (en) 2013-07-10
RU2013114365A (ru) 2014-10-10
AU2011296574A1 (en) 2013-03-21
KR101939965B1 (ko) 2019-01-18
CN103201292B (zh) 2016-09-14
CA2809568A1 (en) 2012-03-08
MX354535B (es) 2018-03-09
MX2013002390A (es) 2013-08-27
NZ624382A (en) 2015-05-29
SG187953A1 (en) 2013-03-28
CN103201292A (zh) 2013-07-10
MY165160A (en) 2018-02-28
CL2013000586A1 (es) 2013-08-30
KR20130111550A (ko) 2013-10-10
NZ608813A (en) 2014-11-28
US20170233465A1 (en) 2017-08-17
TR201903101T4 (tr) 2019-03-21
EP2611831B1 (en) 2018-12-12
SG10201506909PA (en) 2015-10-29
RU2637088C2 (ru) 2017-11-29
US20130330352A1 (en) 2013-12-12
PH12013500411A1 (en) 2022-03-30
JP2013542179A (ja) 2013-11-21
JP2017193543A (ja) 2017-10-26
BR112013004850B1 (pt) 2020-04-07
BR112013004850A2 (pt) 2016-05-31
JP6377348B2 (ja) 2018-08-22
US10633437B2 (en) 2020-04-28
WO2012030394A1 (en) 2012-03-08
CA2809568C (en) 2019-06-11

Similar Documents

Publication Publication Date Title
IL225018A (en) Beta tgf barriers for use in reducing myocardial infarction
PL2927224T3 (pl) Antagoniści receptora
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
ZA201500215B (en) Inhibitors of the fibroblast growth factor receptor
ZA201204966B (en) Inter-frequency positioning measurements
GB201004554D0 (en) Superconducting materials
ZA201207292B (en) Cgrp receptor antagonist
IL224435B (en) Agonists and chimeric antagonists for the 1-il receptor type 1
ZA201308816B (en) Trpv4 antagonists
GB201410398D0 (en) Muscarinic m1 receptor agonists
GB2480614B (en) Switched arrangement for switched mode supply
EP2720546A4 (en) TRPV4 Antagonist
HUE039607T2 (hu) Progeszteron antagonisták
ZA201305576B (en) Trpm8 receptor antagonists
IL232503A (en) H2 - Indazoles as antagonists of the ep2 receptor
EP2620160A4 (en) COMPOSITIONS FOR ORAL ADMINISTRATION
EP2720697A4 (en) TRPV4 Antagonist
EP2549872A4 (en) TRPV4 Antagonist
ZA201301561B (en) 5-ht2b receptor antagonists
TWM385441U (en) Structure for hand tool
GB201008323D0 (en) Telescopic art kiosk
GB201008486D0 (en) Powder dispenser for use with consumable goods
GB0922455D0 (en) Ep2 receptor antagonists
GB201017282D0 (en) Agents for use with antimicrobials
GB201005633D0 (en) Tool for retrieving detachable flat mopping layers

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed